Share on StockTwits

Equities researchers at RBC Capital started coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report issued on Tuesday, reports. The firm set an “outperform” rating and a $12.00 price target on the stock. RBC Capital’s price objective indicates a potential upside of 76.99% from the company’s current price.

Agile Therapeutics (NASDAQ:AGRX) traded up 8.26% during mid-day trading on Tuesday, hitting $7.34. The stock had a trading volume of 357,912 shares. Agile Therapeutics has a 52 week low of $5.05 and a 52 week high of $6.92. The stock has a 50-day moving average of $6.14 and a 200-day moving average of $6.14. The company’s market cap is $136.5 million.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company focused on the development and commercialization of new prescription contraceptive products.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.